Mission Therapeutics
PrivateLast Round
Series D
Extension
Oct 15, 2025
Est. Valuation
$115.4M
Total Funding Raised
$183.55M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Mission Therapeutics is a pharmaceutical research and drug discovery company that develops first-in-class therapeutics targeting deubiquitylating enzymes to treat serious diseases including neurodegenerative conditions, fibrosis, and rare mitochondrial disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mission Therapeutics Comparables
Compare Mission Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NRG Therapeutics | 80% | |
| Casma Therapeutics | 73% | |
| NodThera | 71% |
Mission Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D Extension | Oct 15, 2025 | ||||
| Grant | Jul 2, 2024 | ||||
| Series D | Mar 14, 2024 | ||||
| Grant | Oct 12, 2021 | ||||
| VC Round | Jul 6, 2020 | ||||
Series C | Feb 2, 2016 |
Mission Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Roche Venture Fund | Series A, Series C, Series B, VC Round, Series D Extension, Series D |
| IP Group | VC Round, Series D, Series D Extension |
| Parkinson's UK | Grant |
| Woodford Investment Management | Series C |
| Innovate UK | Grant |
| Roche Venture Fund | Series B, VC Round, Series D, Series D Extension, Series A, Series C |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors increased 43% MoM, reaching 3.7K.
- Jul 24, 2026
Monthly visitors increased 36% MoM.
Recent news
Latest coverage and updates
- is_developingOct 15, 2026
Mission Therapeutics is currently developing MTX325, a CNS-targeting small molecule drug that inhibits mitochondrial DUB enzyme USP30 to promote clearance of dysfunctional mitochondria and improve cellular health.
- partners_withSep 14, 2026
Mission Therapeutics partners with Neuralight, Inc..
Mission Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Mission Therapeutics's valuation, stock price, and market status.
Is Mission Therapeutics a public or private company?
Mission Therapeutics is a private company.
What is the current stock price of Mission Therapeutics?
Mission Therapeutics is a private company, so its shares have no public market price. Caplight tracks Mission Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mission Therapeutics worth (valuation)?
Mission Therapeutics's valuation is estimated at $115.4M based on funding round data.
Can I buy Mission Therapeutics stock?
Mission Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mission Therapeutics's last funding round?
Mission Therapeutics's most recent funding round was Series D Extension on October 15, 2025.
Who are the main investors in Mission Therapeutics?
Key investors in Mission Therapeutics include Roche Venture Fund, IP Group, Woodford Investment Management, Roche Venture Fund, Imperial Innovations.
Will Mission Therapeutics IPO soon?
No public IPO plans have been announced for Mission Therapeutics.
How can I track Mission Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Mission Therapeutics's shares on secondary markets.